Abstract
Background
Static imaging of amino acids does not allow differentiation of low versus high grade brain tumours. It has been shown that dynamic imaging of the amino acid analogue 18F-fluoroethyltyrosine (FET) can achieve this goal. In many centres, 11C-methionine (MET) is used for tumour imaging, but no clinical studies on the use of dynamic scanning for grading have been performed.
Methods
Thirty-four patients with primary brain glioma and histopathological confirmation were retrospectively studied using 40 min dynamic MET–PET with 220 MBq 11C-methionine. In relation to histopathological grading, various metabolic indices and temporal parameters as documented by Poepperl et al. (JNM 2006;47:393–403) were analyzed.
Results
None of the evaluated static or temporal parameters allowed discrimination between high and low grade tumours. On average, low grade tumours showed washout after the initial uptake maximum, while both increases and decreases were seen for high grade tumours. Only the relative early versus late uptake ratio showed a trend towards significance (−0.16 ± 0.17 for low grade versus 0.01 ± 0.25 for high grade; p = 0.07).
Conclusion
Unlike FET–PET, the uptake characteristics of MET-PET do not allow classification of low and high grade tumours on an individual patient basis. Since literature data indicate that both tracers have a similar performance regarding biopsy location, tumour delineation, and detection of recurrence, FET–PET should be advocated over MET–PET as its uptake mechanism also allows noninvasive grading in glioma.
References
Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms–an update on the multidisciplinary management of malignant glioma. Oncologist 2006;11:165–80.
Riemann B, Papke K, Hoess N, et al. Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT. Radiology 2002;225:567–74.
Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx 2005;2:333–47.
Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45.
Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006;27:1432–37.
Weber WA, Dick S, Reidl G, et al. Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med 2001;42:1144–150.
Popperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47:393–403.
Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422–9.
Meier C, Ristic Z, Klauser S, Verrey F. Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J 2002;21:580–9.
Stober B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 2006;33:932–9.
Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999;40:205–12.
Acknowledgements
The authors thank the PET radiopharmacy staff for their competent aid. KVL is Senior Clinical Investigator of the Research Foundation—Flanders (Belgium) (FWO).
Author information
Authors and Affiliations
Corresponding author
Additional information
The first two authors contributed equally to this manuscript.
Rights and permissions
About this article
Cite this article
Moulin-Romsée, G., D’Hondt, E., de Groot, T. et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging : does it work for 11C-Methionine?. Eur J Nucl Med Mol Imaging 34, 2082–2087 (2007). https://doi.org/10.1007/s00259-007-0557-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-007-0557-4